Taarifa zaidi ― Kiswahili

Keratoacanthoma (KA) ni uvimbe wa ngozi wa mara kwa mara unaojulikana kwa ukuaji wake wa haraka na uwezekano wa kujirudia wenyewe. Mara nyingi hutokea kwa wanaume wazee, wenye ngozi nzuri na historia ya uharibifu wa jua. Ingawa kuondolewa kwa upasuaji kwa kukata au upasuaji wa micrographic wa Mohs ndiyo matibabu ya kawaida, kuna njia nyingine mbalimbali za matibabu zinazopatikana.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.

Keratoacanthoma (KA) ni uvimbe wa kiwango cha chini unaoanzia kwenye tezi fulani kwenye ngozi na hufanana na squamous cell carcinoma (SCC) kwa kutumia darubini. Kuna mjadala unaoendelea kuhusu kama KA inafaa kuainishwa kama aina ya SCC vamizi.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.

Cutaneous squamous cell carcinoma (cSCC) ni aina ya pili ya saratani kwa watu, haswa kati ya wazee. Upasuaji kwa kawaida hutumiwa kutibu cSCC, lakini kwa baadhi ya wagonjwa ambao hawawezi kufanyiwa upasuaji au kuchagua kutofanya upasuaji, chaguzi nyingine kama vile matibabu ya ndani ya kidonda zinaweza kuzingatiwa. Matibabu ya kitamaduni ya ndani ya kidonda (methotrexate or 5-fluorouracil) yametumika, lakini kuna utafiti unaoendelea kuhusu mbinu mpya kama vile tiba ya kinga ya ndani ya kichwa na matibabu ya viroba ya oncolytic. Hapa, tutaangalia matibabu tofauti ya ndani kwa cSCC, kuanzia mbinu za kisasa hadi mikakati ya kisasa.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.